Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Change in Acquisitions & Divestments: 2017-2025

Historic Change in Acquisitions & Divestments for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to $107.1 million.

  • Denali Therapeutics' Change in Acquisitions & Divestments fell 45.92% to $107.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $782.0 million, marking a year-over-year decrease of 39.62%. This contributed to the annual value of $1.2 billion for FY2024, which is 44.26% down from last year.
  • As of Q3 2025, Denali Therapeutics' Change in Acquisitions & Divestments stood at $107.1 million, which was down 33.99% from $162.2 million recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Change in Acquisitions & Divestments peaked at $601.1 million during Q3 2023, and registered a low of $107.1 million during Q3 2025.
  • Over the past 3 years, Denali Therapeutics' median Change in Acquisitions & Divestments value was $351.0 million (recorded in 2024), while the average stood at $333.1 million.
  • Per our database at Business Quant, Denali Therapeutics' Change in Acquisitions & Divestments soared by 316.46% in 2023 and then plummeted by 67.06% in 2024.
  • Quarterly analysis of 5 years shows Denali Therapeutics' Change in Acquisitions & Divestments stood at $193.8 million in 2021, then spiked by 87.87% to $364.0 million in 2022, then soared by 34.34% to $489.0 million in 2023, then dropped by 28.22% to $351.0 million in 2024, then plummeted by 45.92% to $107.1 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $107.1 million for Q3 2025, versus $162.2 million for Q2 2025 and $161.8 million for Q1 2025.